Vimarsana
Biggest News Aggregation in the World

Aptorum Group Form News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aptorum Group Form. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aptorum Group Form Today - Breaking & Trending Today

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update - Vimarsana News

Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial...

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023 - Vimarsana News

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023

Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and...

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders - Vimarsana News

Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders

Aptorum Group Limited , a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its...

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets - Vimarsana News

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Limited , a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Nasdaq Stock Market LLC Listing Qualifications Department notifying... -Today at 02:58 am- MarketScreener

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma - Vimarsana News

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has submitted t...